COMP <GO>
CLYM vs CRMD // EV/EBITDA & P/E VALUATION
Climb Bio Inc. (NASDAQ) VS. CorMedix Inc. (NASDAQ) • 15-METRIC TALLY: CLYM 1
— CRMD 3
■ METRIC PARITY
LAST: $10.33 (+2.08%) • MKT CAP: $593.3M
valuation
—
LAST: $7.64 (-6.83%) • MKT CAP: $595.5M
valuation
3.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLYM VS. CRMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLYM | CRMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 45.50% | -80.50 | CRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 3.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.19% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 48.20% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 52.30% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 1.81 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 8/9 | -5.00 | CRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.1 | 25.3 | +18.81 | CLYM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 3.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $593.3M | $595.5M | -$2.2M | CRMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLYM REV | CRMD REV | CLYM GROSS % | CRMD GROSS % | CLYM FCF | CRMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $311.7M | — | 88.5% | -$54.5M | $172.8M |
| FY 2024 | $0 | $43.5M | — | 92.7% | -$15.6M | -$50.7M |
| FY 2023 | $0 | $0 | — | — | -$20.6M | -$38.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLYM // BETA —
CRMD // BETA —